Bristol-Myers Squibb has selected the Medidata Clinical Cloud to help manage, monitor and analyze its clinical trials.
Medidata’s cutting-edge technology platform will support Bristol-Myers Squibb’s research capabilities in immuno-oncology, oncology, immunoscience, virology, cardiovascular, fibrotic diseases, genetically modified diseases and metabolics.
The Medidata platform has been used by more than 630 customers around the world – supporting more than 11,000 clinical studies, 420,000 investigational sites and more than 3.1 million trial volunteers – driving a transformation in clinical trial design and execution, leading to better science and new medical breakthroughs for patients.
Bristol-Myers Squibb will integrate Medidata’s data management, data analytics and risk-based monitoring (RBM) capabilities into all stages of its drug development process.
“Our agreement with Bristol-Myers Squibb is a great example of how the world’s best clinical researchers are increasingly relying on Medidata technology to help support advances in treatments for patients,” said Medidata’s chief executive officer Tarek Sherif.
“Medidata has developed the most comprehensive cloud platform dedicated to clinical research, powered by the world’s largest data repository. With our powerful and flexible SaaS solution, we are helping our customers achieve meaningful time-to-market results, as well as giving them the data and actionable insights they need to innovate successfully.”
In adopting the Medidata Clinical Cloud platform across therapeutic areas, Bristol-Myers Squibb will utilize a full suite of Medidata solutions, including Medidata Rave for electronic data capture, management and reporting and Medidata’s RBM solutions, Medidata TSDV and Medidata CSA, enabling better prioritization of resources around key areas of risk, such as patient safety and data quality and integrity.
A phased rollout is under way. Medidata has selected Accenture, a leading global professional services company providing a broad range of services and solutions in strategy, consulting, digital, technology and operations, to be its partner for specific elements of the transformation project.